For research use only. Not for therapeutic Use.
NRC-2694 is an epidermal growth factor receptor (EGFR) antagonist with anti-cancer and anti-proliferative properties. NRC-2694 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
NRC-2694 at 80 ng (190 nm) concentrations causes comparable inhibition of EGFR expression[1].
In toxicity studies, the maximum tolerated dose of NRC-2694 in male and female mice is 2000 mg/kg (po). NRC-2694 (10 mg/kg) regresses the tumor in mice[1].
| Catalog Number | I008353 |
| CAS Number | 936446-61-6 |
| Synonyms | N-(3-ethynylphenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine |
| Molecular Formula | C24H26N4O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C24H26N4O3/c1-3-18-6-4-7-19(14-18)27-24-20-15-23(22(29-2)16-21(20)25-17-26-24)31-11-5-8-28-9-12-30-13-10-28/h1,4,6-7,14-17H,5,8-13H2,2H3,(H,25,26,27) |
| InChIKey | WBKHQQZRHCECKK-UHFFFAOYSA-N |
| SMILES | COC1=C(C=C2C(=C1)N=CN=C2NC3=CC=CC(=C3)C#C)OCCCN4CCOCC4 |
| Reference | [1]. Ramanadham Jyothi Prasad, et al. 6-7,dialkoxy quinazoline derivatives useful for treatment of cancer related disorders. US 8143250 B2 |
